UDCA (Ursodeoxycholic Acid) is a naturally occurring bile acid approved by the FDA for treating primary biliary cirrhosis and dissolving gallstones. It works by reducing toxic bile acid levels in the liver, improving bile flow, and potentially exhibiting anti-apoptotic and anti-inflammatory effects. TUDCA (Tauroursodeoxycholic Acid) is a taurine-conjugated form with enhanced bioavailability and cellular protective properties.

Mechanism of Action

Mechanism of Action: UDCA

Bile Acid Pool Modification

UDCA is a naturally occurring hydrophilic bile acid that constitutes less than 5% of the endogenous bile acid pool. Therapeutic supplementation increases its proportion to 40-60%, fundamentally altering bile composition. Hydrophilic UDCA competitively displaces hepatotoxic hydrophobic bile acids (chenodeoxycholic acid, deoxycholic acid, lithocholic acid) from both the circulating bile acid pool and hepatocyte/cholangiocyte membranes.

Choleresis and Biliary Protection

UDCA stimulates hepatocyte secretory capacity through post-transcriptional insertion of transport proteins (BSEP, MRP2, AE2) into the canalicular membrane and upregulation of their expression. Enhanced biliary secretion (choleresis) flushes toxic bile acid accumulations, protecting against cholestatic injury. In cholangiocytes, UDCA promotes bicarbonate-rich secretion (the "bicarbonate umbrella") that protects biliary epithelium from bile acid damage.

Mitochondrial Protection

Toxic bile acids induce apoptosis through the mitochondrial pathway. UDCA counteracts this by stabilizing mitochondrial membranes, preventing reactive oxygen species generation, and inhibiting the mitochondrial permeability transition. It directly interacts with Bax to prevent its oligomerization in the outer mitochondrial membrane, blocking cytochrome c release.

Clinical Applications

UDCA is the first-line treatment for primary biliary cholangitis (PBC), where it slows disease progression and improves transplant-free survival. It is also used in primary sclerosing cholangitis (PSC), gallstone dissolution, intrahepatic cholestasis of pregnancy, and cystic fibrosis-associated liver disease. Its efficacy in PBC is attributed to the combination of choleretic, cytoprotective, and immunomodulatory actions.

Glucocorticoid Receptor Modulation

UDCA has been shown to activate the glucocorticoid receptor (GR) in intestinal epithelial cells, which may contribute to its anti-inflammatory effects in the GI tract independent of bile acid receptor signaling.

Research

Safety Profile

Safety Profile: UDCA (Ursodeoxycholic Acid)

Common Side Effects

• Diarrhea (most frequent; dose-dependent)
• Nausea, vomiting, and dyspepsia
• Abdominal pain and bloating
• Pruritus (may transiently worsen before improving in cholestatic conditions)
• Back pain and arthralgia
• Headache and dizziness
• Hair thinning (rare)

Serious Adverse Effects

• Gallstone calcification: In rare cases, dissolution therapy may lead to calcification of previously radiolucent stones, rendering them non-dissolvable
• Hepatotoxicity in PSC: The HALT-PSC trial showed high-dose UDCA (28–30 mg/kg/day) worsened outcomes in primary sclerosing cholangitis; standard doses (13–15 mg/kg/day) remain controversial
• Rare severe diarrhea leading to dehydration and electrolyte imbalance
• Rare allergic reactions

Contraindications

• Complete biliary obstruction or non-functioning gallbladder
• Calcified, radiopaque, or bile pigment gallstones
• Acute cholecystitis or biliary tract infections
• Chronic liver disease with portal hypertension and advanced cirrhosis (relative)
• Known hypersensitivity to bile acids

Drug Interactions

• Bile acid sequestrants (cholestyramine, colestipol): Bind UDCA and prevent absorption; separate by 4+ hours
• Aluminum-containing antacids: Reduce UDCA absorption
• Cyclosporine: UDCA may increase cyclosporine absorption; monitor drug levels
• Oral contraceptives, estrogens, lipid-lowering agents (clofibrate): May increase biliary cholesterol and counteract UDCA's stone-dissolving efficacy
• Ciprofloxacin: Some evidence of altered absorption

Population-Specific Considerations

• Primary biliary cholangitis (PBC): FDA-approved and standard of care; 13–15 mg/kg/day in divided doses
• Gallstone dissolution: Effective for small (<2 cm) radiolucent cholesterol gallstones in patients who refuse or cannot undergo surgery; takes 6–24 months
• Intrahepatic cholestasis of pregnancy: Widely used and generally safe; reduces pruritus and may reduce adverse fetal outcomes
• Cystic fibrosis: Used for CF-associated liver disease; pediatric safety data available
• Bariatric surgery: Sometimes used to prevent gallstone formation post-surgery
• Monitoring: Liver function tests at baseline and periodically; ultrasound for gallstone patients every 6–12 months

Pharmacokinetic Profile